Hey, yesterday's presentation included some new info on a pivotal trial for PanCa to begin in March/April 2014. CEO said INCY has an SPA and the FDA has also granted orphan drug status in PanCa, thus providing accelerated approval as well. They will be recruiting 300 patients in the trial, with overall survival as the endpoint. BUT, they did not say anything about the length of the trial. Given that is PanCa, with very short survival times in the second line setting, would you guess that is a 6 month study, or would it need to be 12 months?
I'd guess on shorter rather than longer. Do I have it right that this is still second-line treatment (I haven't looked at the transcript yet)? That would also argue for shorter. But because the drug is already marketed, announcement of the protocol (including the inclusion criteria) and the expected halfway review for futility may both be commercially important.